Keytruda gets okay from FDA for adjuvant melanoma
Opdivo performed better than BMS’ Yervoy in clinical trial.
UK biotech leading in the nascent field of TCR immunotherapy has appointed Andrew Hotchkiss as its new Chief Commercial Officer.
Novartis’ rival combination better value, says NICE.
Drug only approved when systemic immunotherapies are not suitable
Sanofi steals a march on rivals Amgen
A round-up of this week’s top digital healthcare news. Marco Ricci reports.